| Catalog No. | Size | Price (USD) |
| 100696-T02-50 | 50 µL | $147.96 |
| 100696-T02-100 | 100 µL | $251.64 |
| 100696-T02-200 | 200 µL | $355.32 |
General Information
| Product name | Anti-BRCA1 Antibody, Rabbit Polyclonal |
| Validated applications | ICC/IF (FAQ Protocol) |
| Species reactivity | Reacts with: Human |
| Specificity | Human BRCA1 |
| Immunogen | A synthetic peptide corresponding to the C-terminus of the Human BRCA1 |
| Preparation | Produced in rabbits immunized with a synthetic peptide corresponding to the C-terminus of the Human BRCA1, and purified by antigen affinity chromatography. |
| Source | Polyclonal Rabbit IgG |
| Purification | Protein A & Antigen Affinity |
| Formulation | 0.2 μm filtered solution in PBS |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Synonyms: Anti-BRCAI Antibody; Anti-BRCC1 Antibody; Anti-BROVCA1 Antibody; Anti-FANCS Antibody; Anti-IRIS Antibody; Anti-PNCA4 Antibody; Anti-PPP1R53 Antibody; Anti-PSCP Antibody; Anti-RNF53 Antibody
Image / Experimental Information
| Image 1 Description | Immunofluorescence staining of BRCA1 in HeLa cells. Cells were fixed with 4% PFA,blocked with 10% serum. Then incubated with rabbit anti-human BRCA1 polyclonal antibody (1:1000)(Figure A), incubated with rabbit anti-human BRCA1 polyclonal antibody and antigen (Figure B) at 4℃ overnight. Then cells were stained with the Alexa Fluor®488-conjugated Goat Anti-rabbit IgG secondary antibody (green) and counterstained with DAPI (blue). Positive staining was localized to cytoplasm and nucleus. |
| Image 1 Alt Text | Human BRCA1 Immunohistochemistry(IHC) 3076 |
| Image 1 URL | Source image |
Background Information
| Full Name | breast cancer 1, early onset |
| Description | BRCA1, a breast and ovarian cancer susceptibility gene, encodes a 220-kDa protein. BRCA1 contains an N-terminal RING finger that mediates protein-protein interaction. The C-terminal domain of BRCA1 (BRCT) can activate transcription and interacts with RNA polymerase holoenzyme. BRCA1 in transcriptional activation of ATF1 target genes, some of which are involved in the transcriptional response to DNA damage. The BRCA1 gene encodes a tumor suppressor that is mutated in 50% of familial breast cancers. The BRCA1 protein has been implicated in the DNA damage response, as DNA damage induces the phosphorylation of BRCA1 and causes its recruitment into nuclear foci that contain DNA repair proteins. BRCA1 is involved in the regulation of multiple nuclear events including transcription. AD1, one of the two trans-activation domains in BRCA1, stimulates transcription in a cell context-dependent manner. The coiled-coil-mediated cooperation between BRCA1 and JunB may facilitate the function of these proteins in tissue-specific transcriptional regulation and tumor suppression. Germline mutations in the breast cancer susceptibility genes, BRCA1 and BRCA2, are thought to account for a large portion of familial breast cancer. BRCA1 and BRCA2 participate in cell cycle progression, apoptosis, and DNA repair pathways. |
| Research Areas |
|
| Related Pathways |
|
-HB08DE0517-1ug-HeLa-IF.png){kind=link}